Cargando…

Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy

BACKGROUND AND AIMS: Immune checkpoint inhibitors (ICI) are increasingly used in cancer therapy. Elevated liver enzymes frequently occur in patients treated with ICI but evaluation is poorly described. We sought to better understand causes of liver enzyme elevation, investigation and management. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cunningham, Morven, Iafolla, Marco, Kanjanapan, Yada, Cerocchi, Orlando, Butler, Marcus, Siu, Lillian L., Bedard, Philippe L., Ross, Kendra, Hansen, Bettina, Spreafico, Anna, Feld, Jordan J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195413/ https://www.ncbi.nlm.nih.gov/pubmed/34115819 http://dx.doi.org/10.1371/journal.pone.0253070

Ejemplares similares

A242 DELAYED STEROID TAPER MAY REDUCE RISK OF RELAPSE IN PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR ASSOCIATED HEPATOTOXICIT
por: Almousawi, F, et al.
Publicado: (2023)

Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy
por: Kanjanapan, Yada, et al.
Publicado: (2020)

Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index
por: Day, Daphne, et al.
Publicado: (2019)

Noninvasive Predictors of High-Risk Varices in Patients with Non-Cirrhotic Portal Hypertension
por: Cunningham, Morven E., et al.
Publicado: (2019)

Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting
por: Kanjanapan, Yada, et al.
Publicado: (2023)

Checkpoint Inhibitors and Hepatotoxicity
por: Malnick, Stephen D. H., et al.
Publicado: (2021)

Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry
por: Music, Milena, et al.
Publicado: (2020)

Cancer patients’ experiences with immune checkpoint modulators: A qualitative study
por: Ala‐Leppilampi, Kari, et al.
Publicado: (2020)

Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis
por: Iafolla, Marco A J, et al.
Publicado: (2020)

Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors
por: Kelly, Deirdre, et al.
Publicado: (2021)

Immunotherapy-induced Hepatotoxicity: A Review
por: Da Cunha, Teresa, et al.
Publicado: (2022)

Increasing operational and scientific efficiency in clinical trials
por: Kelly, Deirdre, et al.
Publicado: (2020)

The Role of Myeloid Cells in Hepatotoxicity Related to Cancer Immunotherapy
por: Gudd, Cathrin L. C., et al.
Publicado: (2022)

Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)
por: Genta, Sofia, et al.
Publicado: (2023)

Immune checkpoint inhibitor-related hepatotoxicity: A review
por: Remash, Devika, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologists’ Perspectives
por: Farshidpour, Maham, et al.
Publicado: (2022)

Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known
por: Zheng, Caiyun, et al.
Publicado: (2023)

Overlapping Hepatotoxicity and Colitis Associated with Immune Checkpoint Inhibitors
por: Malik, Alexander, et al.
Publicado: (2023)

Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy
por: Spiliopoulou, Pavlina, et al.
Publicado: (2023)

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
por: Oliva, M, et al.
Publicado: (2019)

Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
por: Personeni, Nicola, et al.
Publicado: (2021)

Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy
por: Araujo, Daniel V, et al.
Publicado: (2021)

Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events
por: Araujo, Daniel V., et al.
Publicado: (2021)

Checkpoint inhibitor-induced hepatotoxicity: Role of liver biopsy and management approach
por: Bessone, Fernando, et al.
Publicado: (2022)

The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity
por: Xing, Hui, et al.
Publicado: (2023)

Longitudinal Strain and Troponin I Elevation in Patients Undergoing Immune Checkpoint Inhibitor Therapy
por: Tamura, Yudai, et al.
Publicado: (2022)

Immune checkpoint inhibitor-related myocarditis: an illustrative case series of applying the updated Cardiovascular Magnetic Resonance Lake Louise Criteria
por: Wintersperger, Bernd J, et al.
Publicado: (2022)

Hepatotoxicity in immune checkpoint inhibitors: A pharmacovigilance study from 2014–2021
por: Xu, Ze, et al.
Publicado: (2023)

Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study
por: Lapointe-Shaw, Lauren, et al.
Publicado: (2018)

Alternative Checkpoints as Targets for Immunotherapy
por: Pant, Ayush, et al.
Publicado: (2020)

Cancer immunotherapy beyond immune checkpoint inhibitors
por: Marin-Acevedo, Julian A., et al.
Publicado: (2018)

Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer
por: Johns, Andrew C, et al.
Publicado: (2023)

Benign elevations in serum aminotransferases and biomarkers of hepatotoxicity in healthy volunteers treated with cholestyramine
por: Singhal, Rohit, et al.
Publicado: (2014)

Glut-1 expression in small cervical biopsies is prognostic in cervical cancers treated with chemoradiation
por: Kanjanapan, Yada, et al.
Publicado: (2017)

Incidence, mortality, and risk factors of immunotherapy-associated hepatotoxicity: A nationwide hospitalization analysis()
por: Weissman, Simcha, et al.
Publicado: (2021)

A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events
por: Janse van Rensburg, Helena J., et al.
Publicado: (2023)

Immune checkpoints and immunotherapy for colorectal cancer
por: Singh, Preet Paul, et al.
Publicado: (2015)

Immune checkpoint signaling and cancer immunotherapy
por: He, Xing, et al.
Publicado: (2020)

NK Cell Dysfunction and Checkpoint Immunotherapy
por: Bi, Jiacheng, et al.
Publicado: (2019)

Resistance to Checkpoint Inhibition in Cancer Immunotherapy
por: Barrueto, Luisa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h1jj3t5lbg7vuv1plnt5rj3kml